Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 28, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific insider trading activities and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific transaction by Mr. J Ziegler:
- Option Exercise: On October 28, 2005, Mr. Ziegler exercised options over 21,596 ADSs granted on November 21, 1996, under the SmithKline Beecham US 1991 Share Option Plan at a price of $28.159 per ADS.
- Share Sale: On the same date, Mr. Ziegler sold 21,596 ADSs at a price of $52.45 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is strictly a compliance notification regarding the transaction described above.
Key Facts for Investor Verification
- Verify the total number of ADSs held by Mr. J Ziegler following the October 28, 2005 transaction.
- Confirm the pricing details of the SmithKline Beecham US 1991 Share Option Plan exercise ($28.159 per ADS).
- Review the market price of GSK ADSs on October 28, 2005, to contextualize the sale price of $52.45 per ADS.